58889-64-8

Basic information

• Product Name: D-TYROSINOL
• Synonyms: D-TYROSINOL;(R)-3-(4-HYDROXYPHENYL)-2-AMINO-1-PROPANOL;Tyrosinol,D-;BENZENEPROPANOL, .BETA.-AMINO-4-HYDROXY-, (.BETA.R)-;(R)-4-(2-amino-3-hydroxypropyl)phenol;REF DUPL: D-Tyrosinol;4-((2R)-2-Amino-3-hydroxypropyl)phenol;D-Tyrosinol (R)-4-(2-amino-3-hydroxypropyl)phenol
• CAS NO: 58889-64-8
• Molecular Formula: C₉H₁₃NO₂
• Molecular Weight: 167.21
• Product Categories: Amino alcohols
• Mol File: 58889-64-8.mol

Chemical Properties

• Boiling Point: 375.2 °C at 760 mmHg
• Flash Point: 180.7 °C
• Appearance: /
• Density: 1.205 g/cm³
• Vapor Pressure: 2.7E-06mmHg at 25°C
• Refractive Index: 1.598
• Storage Temp.: 2-8°C
• CAS DataBase Reference: D-TYROSINOL(CAS DataBase Reference)
• NIST Chemistry Reference: D-TYROSINOL(58889-64-8)
• EPA Substance Registry System: D-TYROSINOL(58889-64-8)

Safety Data

• Hazardous Substances Data: 58889-64-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
D-Tyrosinol is used as a bioactive compound for its potential therapeutic applications due to its antioxidant and anti-inflammatory properties. These properties can contribute to the development of treatments for various conditions where oxidative stress and inflammation are factors.
Used in Nutraceutical Industry:
D-Tyrosinol is used as a functional ingredient for its health-promoting benefits. Its presence in dietary supplements and fortified foods can support consumers' health by providing antioxidant and anti-inflammatory support, which may contribute to overall well-being and the prevention of certain diseases.
Used in Biosynthesis Research:
D-Tyrosinol is used as a key intermediate in the biosynthesis of various natural products. Its role in this process is crucial for the development of new pharmaceuticals and nutraceuticals derived from natural sources, potentially leading to the discovery of novel bioactive compounds with unique health benefits.

InChI:InChI=1/C9H13NO2/c10-8(6-11)5-7-1-3-9(12)4-2-7/h1-4,8,11-12H,5-6,10H2/t8-/m1/s1

Upstream product

• 3410-66-0 D-tyrosine methyl ester 
• 402832-84-2 isovaleryl-L-tyrosyl-L-valyl-D-tyrosinol 
• 3728-20-9 D-tyrosine methylester hydrochloride 
• 556-02-5 tyrosine 
• 402832-86-4 n-butyryl-L-tyrosyl-L-leucyl-L-tyrosynol 
• 402832-83-1 isovaleryl-L-tyrosyl-L-valyl-L-tyrosinol 
• 402832-95-5 {(S)-1-[(S)-1-Benzyloxymethyl-2-(4-benzyloxy-phenyl)-ethylcarbamoyl]-3-methyl-butyl}-carbamic acid tert-butyl ester 
• 402830-01-7 isovaleryl-L-tyrosyl-L-valyl-DL-tyrosinal 
• 402832-92-2 {(S)-1-[(S)-1-Benzyloxymethyl-2-(4-benzyloxy-phenyl)-ethylcarbamoyl]-2-methyl-propyl}-carbamic acid tert-butyl ester 
• 402832-91-1 [1-benzyloxymethyl-2-(4-benzyloxy-phenyl)-ethyl]-carbamic acid tert-butyl ester 
• 83345-46-4 N-(tert-butyloxycarbonyl)-L-tyrosinol 
• 402832-88-6 n-butyryl-L-tyrosyl-L-leucyl-D-tyrosynol 

Downstream Products

• 885021-89-6 (Z)-18-Bromo-octadec-9-enoic acid [(R)-1-hydroxymethyl-2-(4-hydroxy-phenyl)-ethyl]-amide 

Relevant articles and documents

Illuminating a Dark Kinase: Structure-Guided Design, Synthesis, and Evaluation of a Potent Nek1 Inhibitor and Its Effects on the Embryonic Zebrafish Pronephros

NIMA-related kinase 1 (Nek1) has lately garnered attention for its widespread function in ciliogenesis, apoptosis, and the DNA-damage response. Despite its involvement in various diseases and its potential as a cancer drug target, no directed medicinal chemistry efforts toward inhibitors against this dark kinase are published. Here, we report the structure-guided design of a potent small-molecule Nek1 inhibitor, starting from a scaffold identified by kinase cross-screening analysis. Seven lead compounds were identified in silico and evaluated for their inhibitory activity. The top compound, 10f, was further profiled for efficacy, toxicity, and bioavailability in a zebrafish polycystic kidney disease model. Administration of 10f caused the expansion of fluorescence-labeled proximal convoluted tubules, supporting our hypothesis that Nek1-inhibition causes cystic kidneys in zebrafish embryos. Compound 10f displayed insignificant inhibition in 48 of 50 kinases in a selectivity test panel. The findings provide a powerful tool to further elucidate the function and pharmacology of this neglected kinase.

Tyropeptins A and B, new proteasome inhibitors produced by Kitasatospora sp. MK993-dF2 II. Structure determination and synthesis

The structures of tyropeptins A and B, new proteasome inhibitors produced by Kitasatospora sp. MK993-dF2, were determined by analysis of various NMR experiments. The 1H and 13C NMR of tyropeptins were complicated due to the presence of an aldehyde group. Therefore, tyropeptins were converted to their alcohols by sodium borohydride. These alcohol derivatives gave assignable NMR spectra. The stereochemistry of tyropeptins were determined by analysis of acid hydrolysis products from tyropeptins, and further confirmed by the total synthesis. The structures of tyropeptins A and B were found to be isovaleryl-L-tyrosyl-L-valyl-DL-tyrosinal and n-butyryl-L-tyrosyl-L-leucyl-DL-tyrosinal, respectively.

New 1,4-anthracene-9,10-dione derivatives as potential anticancer agents

The amino-substituted anthracene-9,10-dione (9,10-anthraquinone) derivatives represent one of the most important classes of potential anticancer agents. To better understand the basic rules governing DNA sequence specificity, we have recently synthesized a new class of d- and l- aminoacyl-anthraquinone derivatives. We have tested these new compounds as cytotoxic agents, and we have correlated their activity with the configuration of the chiral aminoacyl moiety. Molecular modeling studies have been performed to compare the test drugs in terms of steric overlapping. (C) 2000 Elsevier Science S.A.